𝔖 Bobbio Scriptorium
✦   LIBER   ✦

183 Results of treatment in patients with acute myeloid leukemia preceeded by primary myelodysplastic syndrome

✍ Scribed by H. Urbańska-Ryś; E. Krykowski; A. Fronczak; A. Wrzesień-Kuś; M. Blasińska-Morawiec; T. Robak

Book ID
114119415
Publisher
Elsevier Science
Year
1997
Tongue
English
Weight
118 KB
Volume
21
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The clinical significance of soluble CD8
The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome
✍ Barry D. Hock; Judith L. McKenzie; William Nigel Patton; Lisa F. Haring; Ying Ya 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 2 views

## Abstract ## BACKGROUND Levels of the soluble form of CD86 (sCD86) are elevated in a proportion of patients with leukemia. Although it is a potential modulator of antitumor responses, the significance of sCD86 in patients with hematologic malignancies is unknown. ## METHODS The authors evaluat

Results of imatinib mesylate therapy in
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated